摘要
达格列净为钠-葡萄糖协同转运蛋白2抑制剂之一,促使患者的血糖水平明显改善,减轻肥胖并2型糖尿病患者体重,并且有保护肾脏、心血管系统的作用,与其他口服降糖药物或胰岛素联合使用,疗效提升。达格列净在治疗2型糖尿病方面取得显著的进展,这些进展不仅提高治疗效果,还极大地提高患者的生活质量。本文对达格列净治疗2型糖尿病患者的应用进展进行详细综述,以期为临床治疗提供有力参考。
Dapagliflozin is one of the inhibitors of sodium glucose cotransporter 2,it can significantly improve the blood sugar level of patients,reduce the weight of obese patients with type 2 diabetes,and protect the kidney and car⁃diovascular system.It can be used together with other oral hypoglycemic drugs or insulin to improve the efficacy.Dapagliflozin has made significant progress in the treatment of type 2 diabetes,which not only improves the therapeu⁃tic effect,but also greatly improves the quality of life of patients.This article reviews the application progress of dapa⁃gliflozin in the treatment of patients with type 2 diabetes in detail,in order to provide favorable value for clinical treat⁃ment.
作者
许铮铮
何子英
刘悦
XU Zhengzheng;HE Ziying;LIU Yue(Department of Comprehensive,Tongling Third People's Hospital,Tongling,244000,Anhui,China)
出处
《糖尿病新世界》
2025年第12期192-195,共4页
Diabetes New World
关键词
2型糖尿病
慢性疾病
心血管系统
治疗效果
Type 2 diabetes
Chronic disease
Cardiovascular system
Therapeutic effect
作者简介
许铮铮(1986-),女,本科,主治医师,研究方向为慢性病管理。
